Journal of the Chinese Medical Association
Volume 70, Issue 7 , Pages 269-273, July 2007

Clinicopathologic Analysis of Acute Myeloid Leukemia in a Single Institution: Biphenotypic Acute Myeloid Leukemia May Not Be an Aggressive Subtype

  • Ming-Yuan Lee

      Affiliations

    • Department of Pathology and Laboratory Services, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Ming-Yuan Lee, Department of Pathology and Laboratory Services, Koo Foundation Sun Yat-Sen Cancer Center, 125, Lih-Der Road, Pei-Tou District, Taipei 112, Taiwan, R.O.C.
    • ,
  • Tran-Der Tan

      Affiliations

    • Department of Hemato-oncology, Taipei, Taiwan, R.O.C.
    • ,
  • An-Chen Feng

      Affiliations

    • Clinical Protocol Office, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, R.O.C.

Received 15 December 2006; accepted 28 May 2007.

Article Outline

Background

Most acute leukemias are classified as lymphoid or myeloid lineages by standard microscopic morphology, cytochemistry and a panel of immunologic markers. The World Health Organization classification of acute leukemia incorporates morphologic, cytogenetic, immunologic and clinical features to define the entities that are biologically homogeneous and that have clinical relevance. The purpose of this study was to determine the clinicopathologic characteristics of acute myeloid leukemia (AML) in Taiwan.

Methods

Archival tissues from 70 AML patients during the period of 1995 to 2003 were retrieved. Histologic subtype was classified, defined by World Health Organization classification. Clinical data, including age, gender, treatment and outcome, were scrutinized.

Results

There were 37 males and 33 females. The median age at onset of disease was 49 years (range, 2–78 years), which was younger in biphenotypic AML (23.5 years) and older in multilineage dysplasia-related AML (61 years). There were 9 cases (13%) with recurrent cytogenetic abnormality, 7 (10%) multilineage dysplasia-related, 7 (10%) therapy-related, 39 (56%) not other categorized and 8 (11%) of ambiguous lineage. The 2-and 5-year overall survival rates of AML were 26.5% and 20.6%, respectively. Histologic subtype was a significant parameter to determine survival (p < 0.05). The median survivals of therapy-related, multilineage dysplasia-related and biphenotypic AML were 2 months, 9 months and 30.5 months, respectively.

Conclusion

This was a clinicopathologic study of AML in Taiwan. Histologic subtype plays a significant prognostic role. Multilineage dysplasia-and therapy-related AML have worse prognosis. Biphenotypic AML may not be an aggressive subtype.

Key Words:  acute myeloid leukemia , biphenotypic , multilineage dysplasia , therapy-related , WHO classification

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, et al  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL) . Blood . 1998;92:596–599
  2. Bene MC, Castordi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL) . Leukemia . 1995;9:1783–1786
  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French–American–British Cooperative group . Ann Intern Med . 1985;103:620–625
  4. Jaffe ES , Harris NL , Stein H , Vardiman JW . World Health Organization Classification of Tumours. Tumours of Hematopoietic and Lymphoid Tissues . Lyon: LARC Press; 2001;
  5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Rees J, et al  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Party . Blood . 1998;92:2322–2333
  6. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, et al  Correlation of cytogenetic results with immunophenotype, genotype, clinical features and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan . Cancer Genet Cytogenet . 1995;84:60–68
  7. Liang DC, Chang TT, Lin KH, Lin DT, Lu MY, Chen SH, et al  Improved treatment results for childhood acute myeloid leukemia in Taiwan . Leukemia . 2006;20:136–141
  8. Lee MY, Chiou TJ, Bai LY, Hsiao LT, Hung GY, Chang CY, et al. Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: the preliminary experience in Taiwan . J Chin Med Assoc . 2004;67:117–122
  9. Teng CL, Young JH, Hsu SL, Chou G, Kuo IT, Yu CY, et al. Lactate dehydrate, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia . J Chin Med Assoc . 2006;69:534–537
  10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al  International scoring system for evaluating prognosis in myelodysplastic syndromes . Blood . 1997;89:2079–2088
  11. Smith MA , McCaffrey RP , Karp JE . The secondary leukemias: challenges and research directions . J Natl Cancer Inst . 1996;88:407–418
  12. Bredeson CN , Barnett MJ , Horsman DE , Dalal BI , Ragaz J , Phillips GL . Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary . Leuk Lymphoma . 1993;11:141–145
  13. Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, et al  Secondary leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy . Leukemia . 2001;15:963–970
  14. Buccheri V , Matutes E , Dyer MJ , Catovsky D . Lineage commitment in biphenotypic acute leukemia . Leukemia . 1993;7:919–927
  15. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, et al  Outcome of biphenotypic acute leukemia . Haematologica . 1999;84:699–706
  16. Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, et al  Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavorable cytogenetics and p-glycoprotein over-expression . Br J Haematol . 1998;100:147–155
  17. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, et al. Definition of acute biphenotypic leukemia . Haematologica . 1997;82:64–66

PII: S1726-4901(07)70003-5

doi:10.1016/S1726-4901(07)70003-5

Journal of the Chinese Medical Association
Volume 70, Issue 7 , Pages 269-273, July 2007

Article Tools